ホーム/GILD

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze GILD in workspace
GILDNASDAQ/health care

Gilead Sciences, Inc.

$131.40Up+1,57 (+1,21%)
Research reviewed: 2026年7月12日 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Gilead Sciences, Inc. operates in Biotechnology within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Eröffnung
129,68
Hoch
131,67
Tief
127,94
Marktkapitalisierung
163,14 Mrd.
KGV
17.88
52-Wochen-Hoch
--
Dividende
2.530%
Quartalsdividende
--

3-month price context

直近3か月の推移を表示し、フル調査ワークスペースに進む前に短期構造を把握できます。

Investment thesis

Base case
Biktarvy leadership and Yeztugo adoption can sustain treatment and prevention growth. The base case remains conditional on hiv concentration staying manageable.
Bull case
Biktarvy leadership and Yeztugo adoption can sustain treatment and prevention growth. Trodelvy demand and acquired cell-therapy and antibody-drug-conjugate assets can diversify the portfolio. Livdelzi uptake can add a new growth leg alongside established antiviral franchises.
Bear case
Heavy reliance on HIV leaves earnings exposed to competition, payer pressure and patent transitions. Large acquisitions and acquired research charges can consume capital without producing approved products. Manufacturing complexity and intense competition can pressure patient access and cell-therapy sales.
Thesis invalidation
Reassess the thesis if heavy reliance on HIV leaves earnings exposed to competition, payer pressure and patent transitions.

Key catalysts

  • HIV franchise durability

    Biktarvy leadership and Yeztugo adoption can sustain treatment and prevention growth.

  • Oncology expansion

    Trodelvy demand and acquired cell-therapy and antibody-drug-conjugate assets can diversify the portfolio.

  • Liver-disease growth

    Livdelzi uptake can add a new growth leg alongside established antiviral franchises.

Principal risks

  • HIV concentration

    Heavy reliance on HIV leaves earnings exposed to competition, payer pressure and patent transitions.

  • Acquisition and IPR&D

    Large acquisitions and acquired research charges can consume capital without producing approved products.

  • Cell-therapy competition

    Manufacturing complexity and intense competition can pressure patient access and cell-therapy sales.

Latest earnings research

Q1 2026

Gilead's first-quarter 2026 results showed growth in its base business led by HIV, Trodelvy and Livdelzi, with Yeztugo launch progress and substantial pipeline investment and acquisition activity.

Valuation interpretation

  • HIV cash-flow durability provides support, but a higher growth interpretation requires successful diversification into prevention, oncology and liver disease.
  • Pipeline value should be weighed against acquisition spending, clinical attrition and the timing of patent erosion.

Peer research

ABBVAMGNVRTX

Recent news

Trefis · vor 8 Stunden

Own Regeneron For Biotech Growth? Incyte Is Making Its Case.

Motley Fool · vorgestern

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

Zacks · vor 3 Tagen

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

Motley Fool · vor 3 Tagen

2 Recession-Resistant Dividend Stocks to Buy and Hold

Simply Wall St. · vor 4 Tagen

Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?

Simply Wall St. · vor 5 Tagen

Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access

Data and research sources

Research updated: 2026年7月12日 00:00 UTC
3 verified sources
Gilead Sciences Announces First Quarter Financial ResultsGilead Sciences, Inc. · earningsVerified

Fetched: 2026/7/12 0:00:00 UTC

Published: 2026/5/7 0:00:00

Open original source
Gilead Sciences, Inc. Investor RelationsGilead Sciences, Inc. · companyVerified

Fetched: 2026/7/12 0:00:00 UTC

Open original source
Gilead SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 2026/7/12 0:00:00 UTC

Published: 2026/5/7 0:00:00

Open original source

Continue in the research workspace

Keep GILD in context, run a multi-agent analysis, and monitor thesis changes.

Analyze GILD free

リサーチシステム全体を見る

各段階には固有の役割があり、次の段階で検証可能な成果を残します。

リサーチ手法市場レポートを読む銘柄を探す

Continue researching this stock

市場アナリスト

市場アナリスト は コアリサーチ の中で 観察 段階を専門に担い、後続判断の前提を整える役割です。

ファンダメンタルズアナリスト

ファンダメンタルズアナリスト は コアリサーチ の中で 観察 段階を専門に担い、後続判断の前提を整える役割です。

ニュースアナリスト

ニュースアナリスト は コアリサーチ の中で 観察 段階を専門に担い、後続判断の前提を整える役割です。

リスクマネージャー

リスクマネージャー は リスクと監視 の中で 監視 段階を専門に担い、後続判断の前提を整える役割です。